Pear Therapeutics’ three FDA authorised prescriptions available at OptumRx
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Company working on COVID vaccine INO 4800
Deal signed with AOP Orphan for US commercial rights
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Subscribe To Our Newsletter & Stay Updated